Abvc Biopharma (ABVC) Total Current Liabilities (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Total Current Liabilities came in at $5.4 million in Q1 2026, down 19.87% YoY from $6.7 million in Q1 2025, and down 12.51% on a QoQ basis from $6.2 million in Q4 2025.
Abvc Biopharma (ABVC) Total Current Liabilities (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 14 years of Total Current Liabilities data on file, last reported at $5.4 million in Q1 2026.
- Quarterly Total Current Liabilities fell 19.87% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 19.87% YoY) and the FY2025 annual result came in at $6.2 million, down 6.0% from the prior year.
- Total Current Liabilities slipped to $5.4 million in Q1 2026, from $6.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $6.7 million in Q1 2025 to a low of $3.6 million in Q2 2022.
- A 5-year average of $5.6 million and a median of $6.1 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities fell 21.49% — and 2023, when it jumped 58.34%.
- Tracing ABVC's Total Current Liabilities over 5 years: stood at $5.5 million in 2022, then gained by 10.07% to $6.1 million in 2023, then grew by 7.47% to $6.6 million in 2024, then slipped by 6.0% to $6.2 million in 2025, then retreated by 12.51% to $5.4 million in 2026.
- The last three Total Current Liabilities figures came in at $5.4 million (Q1 2026), $6.2 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 630.93 Mn |
| 10 | Abvc Biopharma | 24.23 Mn | 24.23 Mn | - | 5.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.69 Mn |
| Mar 31, 2026 | 5.39 Mn |
| Dec 31, 2025 | 6.16 Mn |
| Sep 30, 2025 | 6.54 Mn |
| Jun 30, 2025 | 6.53 Mn |
| Mar 31, 2025 | 6.73 Mn |
| Dec 31, 2024 | 6.56 Mn |
| Sep 30, 2024 | 6.25 Mn |
| Jun 30, 2024 | 6.25 Mn |
| Mar 31, 2024 | 6.18 Mn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 5.36 Mn |
| Jun 30, 2023 | 5.77 Mn |
| Mar 31, 2023 | 5.07 Mn |
| Dec 31, 2022 | 5.54 Mn |
| Sep 30, 2022 | 3.89 Mn |
| Jun 30, 2022 | 3.65 Mn |
| Mar 31, 2022 | 3.66 Mn |
| Dec 31, 2021 | 3.69 Mn |
| Sep 30, 2021 | 3.44 Mn |